Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tenofovir exalidex (CMX 157) is a lipid-conjugated acyclic nucleotide analog of Tenofovir, demonstrating efficacy against wild-type and antiretroviral-resistant HIV strains, including those resistant to multiple nucleoside/nucleotide analogs. It effectively inhibits all major HIV-1 and HIV-2 subtypes in fresh human PBMCs, as well as all evaluated HIV-1 strains in monocyte-derived macrophages, displaying EC50 values between 0.2 and 7.2 nM. Oral administration of CMX157 shows no apparent toxicity. Additionally, Tenofovir exalidex exhibits antiviral properties against HBV.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 93.00 | |
10 mg | In stock | $ 138.00 | |
25 mg | In stock | $ 229.00 | |
50 mg | In stock | $ 397.00 | |
100 mg | In stock | $ 589.00 |
Description | Tenofovir exalidex (CMX 157) is a lipid-conjugated acyclic nucleotide analog of Tenofovir, demonstrating efficacy against wild-type and antiretroviral-resistant HIV strains, including those resistant to multiple nucleoside/nucleotide analogs. It effectively inhibits all major HIV-1 and HIV-2 subtypes in fresh human PBMCs, as well as all evaluated HIV-1 strains in monocyte-derived macrophages, displaying EC50 values between 0.2 and 7.2 nM. Oral administration of CMX157 shows no apparent toxicity. Additionally, Tenofovir exalidex exhibits antiviral properties against HBV. |
In vitro | Tenofovir exalidex demonstrates over 300-fold greater activity than Tenofovir against a broad spectrum of viruses across various cell systems and shows efficacy against MNR mutants resistant to all current NRTIs. Particularly, in PBMCs, CMX157 exhibits an average EC50 of 2.6 nM (ranging from 0.2 to 7.2 nM) against 27 wild-type HIV-1 isolates from group M subtypes A to G and group O[1]. The mechanism of action involves inhibiting HBV polymerase to prevent HBV DNA elongation, without the involvement of cyclophilins in this process. Moreover, the combination of CRV431 (host-targeting) and Tenofovir exalidex (direct-acting) leads to a synergistic effect in inhibiting HBV DNA synthesis, indicating their actions target different stages of the HBV life cycle[3]. |
In vivo | Tenofovir exalidex (Sprague-Dawley rats) is orally available and has no apparent toxicity when given orally to rats for 7 days at doses of 10, 30, or 100 mg/kg/day[2]. Tenofovir exalidex (5-10 mg/kg; oral gavage; daily for a period of 16 days) decreases liver HBV DNA levels dose-dependently[3]. |
Synonyms | Tenofovir, HDP-Tenofovir, CMX-157, CMX157, CMX 157 |
Molecular Weight | 569.72 |
Formula | C28H52N5O5P |
CAS No. | 911208-73-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Insoluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tenofovir exalidex 911208-73-6 Immunology/Inflammation Antiviral Tenofovir HDP-Tenofovir CMX-157 CMX157 CMX 157 inhibitor inhibit